Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 15/20 | 0.64 |
| ▸ | CDK2 | P24941 | 4/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.56 |
| ▸ | GSK3A | P49840 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4483435 | 0.90 | GSK3B (0.72) | GSK3BCDK2HDAC1HDAC2HDAC8 | |
| SCHEMBL4492471 | 0.87 | GSK3B (0.57) | GSK3BCDK2HDAC1HDAC2HDAC8 | |
| SCHEMBL4506071 | 0.87 | GSK3B (0.62) | GSK3BHDAC1HDAC2HDAC8GSK3A | |
| SCHEMBL4503805 | 0.85 | GSK3B (0.70) | GSK3BCDK2HDAC1HDAC2HDAC8 | |
| SCHEMBL4495289 | 0.85 | GSK3B (0.73) | GSK3BCDK2HDAC1HDAC2HDAC8 | |
| SCHEMBL4492088 | 0.83 | HDAC1 (0.71) | GSK3BHDAC1HDAC2HDAC8 | |
| SCHEMBL4499351 | 0.81 | DYRK1A (0.63) | GSK3BCDK2GSK3ACYP1A2 | |
| SCHEMBL4487751 | 0.80 | GSK3B (0.67) | GSK3BCDK2HDAC1HDAC2HDAC8 | |
| SCHEMBL1460269 | 0.80 | GSK3B (0.70) | GSK3BCDK2HDAC1HDAC2HDAC8 | |
| SCHEMBL628265 | 0.79 | CDK2 (0.66) | GSK3BCDK2GSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7632854-B2 | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2009-12-15 | — | — | US | claimed |
| US-20030134841-A1 | Succinoylamino lactams as inhibitors of A-beta protein production | OLSON RICHARD E (US) | 2003-07-17 | — | — | US | claimed |
| US-7507815-B2 | Succinoylamino lactams as inhibitors of a-β protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-03-24 | — | — | US | disclosed |
| US-20080293692-A1 | SUCCINOYLAMINO LACTAMS AS INHIBITORS OF A-BETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-11-27 | — | — | US | disclosed |
| US-7304055-B2 | Succinoylamino lactams as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-12-04 | — | — | US | disclosed |
| US-20060258638-A1 | Succinoylamino lactams as inhibitors of A-beta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-11-16 | — | — | US | disclosed |
| US-7101870-B2 | Succinoylamino lactams as inhibitors of A-β protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-09-05 | — | — | US | disclosed |
| US-6962913-B2 | Benzo-1,4-diazepin-2-ones as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-11-08 | — | — | US | disclosed |
| US-6794381-B1 | BETA -PEPTIDE INHIBITOR PREVENTS NEUROLOGICAL DEPOSITS OF AMYLOID PRECURSOR PROTEIN; ALZHEIMER'S DISEASE AND DOWN'S SYNDROME TREATMENT | BRISTOL-MYERS SQUIBB COMPANY | 2004-09-21 | — | — | US | disclosed |
| US-20030134841-A1 | Succinoylamino lactams as inhibitors of A-beta protein production | OLSON RICHARD E (US) | 2003-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293692-A1 | SUCCINOYLAMINO LACTAMS AS INHIBITORS OF A-BETA PROTEIN PRODUCTION | BACE1, APH1A, APP | GSK3B 108/4885CDK2 2249/4885HDAC1 2121/4885 |
| US-20060258638-A1 | Succinoylamino lactams as inhibitors of A-beta protein production | BACE1, APH1A, APP | GSK3B 108/4885CDK2 2249/4885HDAC1 2121/4885 |
| US-20030134841-A1 | Succinoylamino lactams as inhibitors of A-beta protein production | APH1A, BACE1, APP | GSK3B 234/4885CDK2 2346/4885HDAC1 2466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.